{{medical}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477241639
| IUPAC_name = 2-amino-''N,N<nowiki>'</nowiki>''- bis[(6''S'',9''R'',10''S'',13''R'',18a''S'')- 6,13-diisopropyl- 2,5,9-trimethyl- 1,4,7,11,14-pentaoxohexadecahydro- 1''H''-pyrrolo[2,1-''i''] [1,4,7,10,13] oxatetraazacyclohexadecin- 10-yl]- 4,6-dimethyl- 3-oxo- 3''H''-phenoxazine- 1,9-dicarboxamide
| image = Actinomycin D.png
| drug_name = 放线菌素D

<!--Clinical data-->
| tradename = Cosmegen
| Drugs.com = {{drugs.com|monograph|dactinomycin}} 
| MedlinePlus = a682224
| pregnancy_category = D
| legal_status = Rx-only 
| routes_of_administration = [[静脉注射|静脉注射]] 

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 5%
| metabolism =  
| elimination_half-life = 36小时

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50-76-0
| ATC_prefix = L01
| ATC_suffix = DA01
| ATC_supplemental =  
| PubChem = 2019
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
 | DrugBank = DB00970
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10482167
| NIAID_ChemDB = 009885
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1CC1JFE158
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = C06770
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 27666
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1554

<!--Chemical data-->
| C=62 | H=86 | N=12 | O=16 
| molecular_weight = 1255.42 g/mol
| InChI = 1/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
| InChIKey = RJURFGZVJUQBHK-IIXSONLDBN
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = RJURFGZVJUQBHK-IIXSONLDSA-N
| synonyms = <small>2-Amino- 4,6-dimethyl- 3-oxo- 3H-phenoxazine- 1,9-dicarboxylic acid bis- [(5,12-diisopropyl- 9,13,16-trimethyl- 4,7,11,14,17-pentaoxo- hexadecahydro- 10-oxa- 3a,6,13,16-tetraaza- cyclopentacyclohexadecen- 8-yl)- amide]</small>
}}

'''放线菌素D'''（{{lang-en|'''Actinomycin D'''或'''Dactinomycin'''}}，简称'''放线菌素'''，又名'''更生霉素'''）是从土壤中[[链霉菌属|链霉菌属]]的[[细菌|细菌]]分离出来的放线菌素类[[多肽类抗生素|多肽类抗生素]]中最重要的一种。<ref name="gen" /> 作为早期的[[化疗|化疗]]药物之一，放线菌素已被使用了很长时间。

==历史==
放线菌素是人类发现的第一种具有抗[[癌|癌]]作用的[[抗生素|抗生素]]。<ref name="gen">{{Cite journal 
| last1 = Hollstein | first1 = U. 
| title = Actinomycin. Chemistry and mechanism of action 
| doi = 10.1021/cr60292a002 
| journal = Chemical Reviews 
| volume = 74 
| issue = 6 
| pages = 625–652 
| year = 1974 
| pmid =  
| pmc = 
}}</ref> 它最早是由[[赛尔曼·A·瓦克斯曼|赛尔曼·A·瓦克斯曼]]和他的同事H.B.伍德拉夫于1940年共同发现。<ref>{{cite journal |author=Waksman S A, Woodruff H B |title=Bacteriostatic and bacteriocidal substances produced by soil actinomycetes|journal=Proc Soc Exper Biol |volume=45 |pages=609–614 |year=1940}}</ref> 在1964年12月10日由美国[[FDA|FDA]]批准之后，放线菌素由[[默克药厂|默克药厂]]以Cosmegen作为商品名销售。

==作用机理==
在[[细胞生物学|细胞生物学]]的研究中，人们发现放线菌素可以抑制[[转录|转录]]过程。它能够在转录起始复合物的位置结合[[DNA|DNA]]，与DNA形成复合体，阻止[[RNA聚合酶|RNA聚合酶]]合成[[RNA|RNA]]。<ref>{{cite journal |author=Sobell H |title=Actinomycin and DNA transcription |journal=Proc Natl Acad Sci USA |volume=82 |issue=16 |pages=5328–31 |year=1985 |pmid=2410919 |doi=10.1073/pnas.82.16.5328 |pmc=390561}}</ref>

== 临床用途 ==
临床上用的放线菌素是清澈、黄色的液体，给药方式为[[静脉注射|静脉注射]]。它主要用来治疗多种癌症，其中包括：
*[[妊娠滋养细胞病|妊娠滋养细胞病]]<ref>{{cite journal |author=Turan T, Karacay O, Tulunay G, Boran N, Koc S, Bozok S, Kose M |title=Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia |journal=Int J Gynecol Cancer |volume=16 |issue=3 |pages=1432–8 |year= 2006|pmid=16803542 |doi=10.1111/j.1525-1438.2006.00606.x}}</ref> 
*[[肾母细胞瘤|肾母细胞瘤]]<ref>{{cite journal |author=Abd El-Aal H, Habib E, Mishrif M |title=Wilms' Tumor: The Experience of the Pediatric Unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) |journal=J Egypt Natl Canc Inst |volume=17 |issue=4 |pages=308–11 |year=2005 |pmid=17102824}}</ref> 
*[[横纹肌肉瘤|横纹肌肉瘤]]<ref>{{cite journal |author=Khatua S, Nair C, Ghosh K |title=Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues |journal=J Pediatr Hematol Oncol |volume=26 |issue=11 |pages=777–9 |year=2004 |pmid=15543019 |doi=10.1097/00043426-200411000-00020}}</ref>
*[[尤文氏肉瘤|尤文氏肉瘤]]<ref>{{Cite journal 
| doi = 10.1002/1097-0142(197611)38:5<1925::AID-CNCR2820380510>3.0.CO;2-J 
| last1 = Jaffe | first1 = N. 
| last2 = Paed | first2 = D. 
| last3 = Traggis | first3 = D. 
| last4 = Salian | first4 = S. 
| last5 = Cassady | first5 = J. R. 
| title = Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy 
| journal = Cancer 
| volume = 38 
| issue = 5 
| pages = 1925–1930 
| year = 1976 
| pmid = 991106
}}</ref>
*恶性[[葡萄胎|葡萄胎]]<ref>{{Cite journal 
| last1 = Uberti | first1 = E. M. H. 
| last2 = Fajardo | first2 = M. D. C. 
| last3 = Ferreira | first3 = S. V. V. R. 
| last4 = Pereira | first4 = M. C. V. 
| last5 = Seger | first5 = R. C. 
| last6 = Moreira | first6 = M. A. L. R. 
| last7 = Torres | first7 = M. D. 
| last8 = De Nápoli | first8 = G. 
| last9 = Schmid | first9 = H. 
| doi = 10.1016/j.ygyno.2009.09.012 
| title = Reproductive outcome after discharge of patients with high-risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy 
| journal = Gynecologic Oncology 
| volume = 115 
| issue = 3 
| pages = 476–481 
| year = 2009 
| pmid = 19818481 
| pmc = 
}}</ref>
有时候放线菌素与其它化疗药物一同用于联合化疗，如用于治疗横纹肌肉瘤和尤因肉瘤的的VAC联合疗法（与[[长春新碱|长春新碱]]和[[环磷酰胺|环磷酰胺]]组成）。

放线菌素还被用作放射增敏剂，因为它能通过抑制癌细胞对亚致死[[辐射|辐射]]伤害的修复及延缓其在辐射之后的代偿性增生，从而提高肿瘤对[[放疗|放疗]]的敏感性。<ref>{{Cite journal 
| last1 = Hagemann | first1 = R. F. 
| last2 = Concannon | first2 = J. P. 
| doi = 10.1259/0007-1285-46-544-302 
| title = Mechanism of intestinal radiosensitization by actinomycin D 
| journal = British Journal of Radiology 
| volume = 46 
| issue = 544 
| pages = 302–308 
| year = 1973 
| pmid =  4720744
| pmc = 
}}</ref>

== 副作用 ==
常见的[[不良反应|不良反应]]包括[[骨髓抑制|骨髓抑制]]、[[疲倦|疲倦]]、[[脱发|脱发]]、[[口腔溃疡|口腔溃疡]]、[[食欲不振|食欲不振]]和[[腹泻|腹泻]]。<ref name="pku">{{cite book | title=抗肿瘤药物手册 | publisher=北京大学医学出版社 | author=孙燕 | year=2006 | location=北京 | isbn=978-7-811-16205-9}}</ref>  

== 研究用途 ==
由于可以和DNA双螺旋结合，放线菌素除了抑制RNA合成之外，也能够影响[[DNA复制|DNA复制]]。不过科学家一般会选择更适合实验室里使用的其它DNA复制抑制剂，如[[羟基脲|羟基脲]]。

放线菌素和它的荧光衍生物7-氨基放线菌素（7-AAD）在[[流式細胞術|流式細胞術]]研究和[[显微镜|显微镜]]观察细胞的过程中被用作染色剂。对富含GC的DNA片段的亲和力使得它们特别适合于标记DNA。7-AAD还能与DNA单链结合，因此它还能用于观察[[细胞凋亡|细胞凋亡]]和分辨活细胞与死细胞。<ref>{{Cite journal 
| doi = 10.1034/j.1600-0609.2000.09005.x 
| last1 = Toba | first1 = K. 
| last2 = Koike | first2 = T. 
| last3 = Watanabe | first3 = K. 
| last4 = Fuse | first4 = I. 
| last5 = Takahashi | first5 = M. 
| last6 = Hashimoto | first6 = S. 
| last7 = Takahashi | first7 = H. 
| last8 = Abe | first8 = T. 
| last9 = Yano | first9 = T. 
| title = Cell kinetic study of normal human bone marrow hematopoiesis and acute leukemia using 7AAD/PY 
| journal = European journal of haematology 
| volume = 64 
| issue = 1 
| pages = 10–21 
| year = 2000 
| pmid = 10680701
}}</ref>

== 参考资料 ==
{{reflist|2}}

== 外部链接 ==
* {{MedlinePlusDrugInfo|medmaster|a682224}}

{{化疗药物}}

[[Category:多肽类抗生素|Category:多肽类抗生素]]
[[Category:環肽|Category:環肽]]
[[Category:DNA复制抑制剂|Category:DNA复制抑制剂]]
[[Category:缩酚酸肽|Category:缩酚酸肽]]
[[Category:IARC第3类致癌物质|Category:IARC第3类致癌物质]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]